Scleral device manages OSD

Article

The Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) device is a useful method of managing ocular surface disease (OSD) and optical imperfections, reveals a new study.

The Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) device is a useful method of managing ocular surface disease (OSD) and optical imperfections, reveals a new study.

A team managed by Dr Ryan Dimit, Alkek Eye Center, Baylor College of Medicine, Houston, Texas, USA, retrospectively reivewed the clinical outcomes of 51 charts of patients fitted unilaterally or bilaterally with the scleral device. The outcome measures included patient demographics, ocular diagnoses, associated systemic conditions, best corrected visual acuity (BCVA) before and after fitting, Visual Function Questionnaire scores (VFQ-25), and ocular surface disease index (OSDI) scores.

The most common reasons for wearing the PROSE device included relieving the symptoms of severe to moderate dry eye syndrome (DES), management of refractive problems and management of various anomalies (the "Other" group).

BCVA improved in wearers for those in with DES or refractive problems by 17 and 10 letters, respectively. However, BCVA did not improve for patients in the "Other" group.

There were no serious complications and the PROSE device is regarded as a useful management option for ophthalmic conditions such as moderate to severe DES and irregular corneal astigmatism.

The paper can be viewed in the Journal of the British Contact Lens Association.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.